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Abstract: Background: excessive and incorrect use of antibiotics is a common event that contributes
to increased bacterial resistance to antibiotics. Based on the European Centre for Disease Control
and Prevention (ECDC) European Surveillance of Antimicrobial Consumption (ESAC)-Net reports,
outpatient antibiotics prescribing in Poland, is higher than the European average rate. However,
ECDC reports do not provide data on consumption in specific patient groups. Additional studies
focused on selected patient groups are needed for a more detailed analysis. The use of antibiotics
during pregnancy is inevitable due to the proven risk of complications in this period, perinatal
infections, and infections in newborns, in the situation of frequent infections of the genital tract,
urinary tract, and asymptomatic bacteriuria in pregnant women. The aim of this study was to analyze
the use of antibiotics/the implementation of antibiotic prescriptions ordered by gynecologists during
pregnancy in pregnant women in Małopolska Voivodeship, with particular emphasis on demographic
data and drug groups. Material and methods: the analysis used data on the reimbursement of
antibiotics from the Małopolska Health Fund for 2013–2014. The database contained information
of a demographic nature: age, place of residence, date of birth, as well as information on the type
of drug, and the number of packages purchased by the patients. Results: the study included 67,917
women. During pregnancy, 23.6% filled their prescriptions for antibiotics. In the first trimester, the
percentage of women filling their prescriptions for antibiotics was the lowest and amounted to 7.8%,
in the second and third trimesters, these were 9.0% and 11.2%, respectively. The inhabitants of rural
areas bought antibiotics more often (23.5%). Most frequently, antibiotics were purchased by women
under 18 years of age (32.1%), but the use of antibiotics in women aged 18–34 and over 35 was
similar, amounting to 23.8% and 22.7%, respectively. Most often (94.78% of cases) monotherapy was
used, including beta-lactams and beta-lactams with an inhibitor (67.3%), then second-generation
cephalosporins (13.5%), macrolides (14.73%), and others. Prescription of two different preparations
was found in 5.06% of cases, three (0.19%), and four or more (0.03%). Conclusions: due to the fact
that studies on antibiotic therapy in pregnant women in Poland are rare, it is impossible to assess the
situation thoroughly. Additionally, in Poland, the prevalence of gestational infections is unknown,
and their diagnostics is important, especially in relation to microbiological diagnostics and targeted
treatment. However, the present results indicate the need to implement broad health promotion
programs, accessible to all women, also those living outside large cities, particularly promoting the
prevention of urinary tract infections and reproductive health in general.
Keywords: pregnancy; antibiotic therapy; defined daily dose; infection prevention
1. Background
Excessive and incorrect use of antibiotics is a common event that contributes to the
growth of bacterial resistance to antibiotics [1]. The results of the European Surveillance of
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Antimicrobial Consumption (ESAC) project implemented in European countries by the
Healthcare-associated Infections Surveillance Network (HAI-Net), European Centre for
Disease Prevention and Control (ECDC), indicate a problem with the use of antibiotics in
Poland in the open health sector. The average consumption in Poland in 2009–2018 was
high: it ranged from 18 to 23.8 DDD/1000 people/day, and showed an upward trend,
while the corresponding values of the European average were 10 to 40% lower, with a
slight (0.3%) downward trend [2]. However, the antibiotic consumption in specific patient
groups is not reported in this project. Obtaining such information requires prospective or
retrospective, targeted studies, which are not very common. In the ECDC study, analyses
were carried out not only with regard to the consumption of all antibacterial drugs, but also
taking into account the consumption of individual groups of antibiotics. A closer analysis
shows that the use of specific groups of antibiotics or their use in specific populations
may be problematic. According to ECDC reports, the consumption rate of trimethoprim
with sulfamethoxazole was particularly high (2012)—twice as high as the European aver-
age [3], and in 2018, twice as high consumption was recorded in the group of "macrolides,
lincosamides, and streptogramins" and in the group "other" (classification used in ECDC
reports) [2]. In the case of trimethoprim/sulfamethoxazole, an interesting observation was
noted in the study by Pomorska-Wesołowksa et al., indicating extremely high resistance of
Staphylococcus aureus to this antibiotic in patients over 80 years of age [4]. The analysis of
trends and the structure of antibiotic consumption reported in the ESAC program coordi-
nated by ECDC also showed that the consumption of fluoroquinolones in Poland is higher
than the European average values and with an upward trend [5]. These data confirmed
the necessity of analysis of antibiotic consumption in specific patient populations. Data on
antibiotic consumption may also be used, especially for a given patient population, to iden-
tify areas of care that require intervention or modification of existing infection prevention
procedures in specific patient populations. For example, the analysis of data on antibiotic
prescriptions for women, in the period of 30 days after childbirth, confirmed, with a very
high probability, the thesis about the lack of effective post-discharge surveillance after
cesarean sections [6,7]. Additionally, the analysis of the use of antibiotics within 30 days
of childbirth showed a significantly higher use of antibiotics in the youngest women and
rural residents, which indicates which groups of patients require special attention. In a
multicenter study in southern Poland, fewer than one patient per 100 had surgical site
infection (SSI) after cesarean delivery, while European data indicate 1.8% [8].
Antibiotics are among the medications most commonly prescribed for pregnant
women [9]. In the United States, pregnant women make up about 10 million people,
i.e., about 3% of the population [10]; in Poland, in recent years, the number of deliveries
has been around 400,000 per year (1% of the population) [11]. The use of antibiotics in
this group of patients is inevitable due to the proven risk of complications in the course of
pregnancy, perinatal infections and infections in newborns, in the situation of frequent in-
fections of the genital tract in pregnant women [12–15], and urinary tract and asymptomatic
bacteriuria [16]. Infection surveillance, including effective treatment, is also associated
with the control of perinatal infections, for example, bacterial vaginosis is one of the most
important prognostic factors for chorioamnionitis [17]; furthermore, chorioamnionitis is
a significant risk factor for morbidity and mortality in neonates [18]. Antibiotics, there-
fore, play an important role in improving and promoting the health of pregnant women.
Nevertheless, as with other therapies, overuse can be counterproductive.
The most important rules concerning antibiotic usage during pregnancy comprise
usage of medications only if absolutely indicated, avoiding, if possible, initiating therapy
during the first trimester, selecting a safe medication (which is often an older drug with an
approved track record in pregnancy), preferring, wherever possible, single-agent therapy
to combination therapy. Moreover, narrow-spectrum antibiotics are preferred over those
with a broad spectrum for the treatment of established infection and intrapartum GBS
chemoprophylaxis. These rules also include the use of the lowest effective dose and
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discouraging the use of over-the-counter drugs, which may interfere with the efficacy
and/or metabolism of prescription medications [19].
The aim of this study, which is a continuation of the cited study, was to analyze the use
of antibiotics/filling antibiotic prescriptions ordered by gynecologists during pregnancy, in
pregnant women in Małopolska Voivodeship, with particular emphasis on demographic
data and drug groups.
2. Materials and Method
The analysis used retrospectively collected data on the reimbursement of antibiotics
from the Małopolska National Health Fund (NHF) for 2013–2014 in relation to data con-
cerning deliveries reimbursed by this payer. For patients who gave birth in 2013 and
2014, owing to the unique system identification number, data on filling the antibiotic
prescriptions ordered by gynecologists in the course of the nine months preceding child-
birth were checked. The database, anonymized by the National Health Fund, contained
selected information of a demographic nature: age and place of residence, date of delivery
(allowing analysis by trimester), as well as information on the type of drug and the number
of packages purchased by the patients. The NHF reimbursement system is based on the
Diagnosis-Related Groups (DRG) and for different types of deliveries following codes
are gathered: N01, N02, N03, N09, N11, N13. N01 represents delivery, N02– multiple or
preterm births, N03– pregnancy or fetal pathology, with childbirth > 5 days, N09–severe
pathology of pregnancy with childbirth, including extended diagnosis, comprehensive
treatment > 6 days, N11– severe pathology of pregnancy with childbirth, including ex-
tended diagnosis, comprehensive treatment > 10 days, N13–severe pathology of pregnancy
ended with operative delivery > 3 days. Therefore, the database does not allowed to
distinguish multiple and preterm birth, and does not include, and the analysis does not
encompass, miscarriages. For analysis, three types of birth were taken into account: single
child (N01), multiple or preterm birth (N02) and pregnancy pathology (N03, N09, N11,
N13 together).
Antibiotic consumption was expressed as the percentage of women with prescrip-
tion and the aggregate sum of defined daily doses (DDD) according to the ATC/DDD
(Anatomical Therapeutic Chemical) system of the World Health Organization, group
“J01” [20]. Only antibiotics for systemic use were taken into account—no antifungal (J02),
antimycobacterial (J04), or antiviral (J05) drugs were included in the analyses. The data re-
ferring to the quantities of antibiotics used are expressed in the World Health Organization
(WHO)-recommended defined daily doses (DDDs, access valid on 27 November, 2020:
http://www.whocc.no/atc_ddd_index/).
The one-time implementation (due to one case of infection) was the purchase of an-
tibiotics based on prescriptions with different purchase dates, if the interval between them
was not longer than 14 days. With the date of delivery known, cases where prescriptions
were filled by individual women up to 280 days before delivery were taken into account,
including the first trimester—up to 182 days, the second trimester, from 92 to 182 days,
and the third trimester—90 days or less before delivery. The results are presented in the
form of the number and percentage of women taking antibiotics during pregnancy in each
trimester and calculated mean values with standard deviation for DDD per one woman tak-
ing antibiotics and per 100 pregnant women. The frequency of taking antibiotics depending
on the selected characteristics of the subjects and childbirth was compared using the Chi2
test, while the distribution of the number of doses using the nonparametric Kruskal–Wallis
test due to the lack of normal distribution of these variables. The differences for which
p < 0.05 were considered statistically significant, but in the case of multiple comparisons,
the Bonferroni correction was applied. The analysis used the IBM SPSS ver. 26.
This work was approved by the Bioethics Committee of Jagiellonian University (ap-
proval no. 122.6120.29.2017). The study was based on the data gathered during routine
patient care and the analysis did not include any individual participant’s data. As a re-
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sult, no consent statements were required from participants. The study in this form was
approved by the local Bioethics Committee of Jagiellonian University.
3. Results
The study included 67,917 women, 23.6% of whom filled their prescriptions for
antibiotics during pregnancy, the mean DDD per patient was 44.7 (Table 1). In the first
trimester, the percentage of women fulfilling their prescriptions for antibiotics was the
lowest and amounted to 7.8%, in the second and third trimesters, it was slightly higher:
9.0% and 11.2%, respectively. Some women filled prescriptions in more than one period,
hence the data from trimesters do not add up to the overall percentage. Antibiotics were
purchased significantly more often by rural women, compared to city dwellers, i.e., 23.5%
and 21.9% of city dwellers, in cities up to and above 100,000 of residents, respectively,
redeemed the prescription for antibiotics vs. 24.4% of female rural residents (p < 0.001)
(Table 2). A similar observation, i.e., the most frequent filling of prescriptions by rural
residents and the youngest women, also applies to individual trimesters (Tables 3–5).
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Table 3. Number of prescriptions and DDD for first trimester of pregnancy according to place of
























16,679 6.9 259.3 (3792.7)
Age
<18 years 393 10.9
p = 0.006
289.7 (1082.9)
p = 0.00618–34 years 57,326 7.9 292.9 (3615.3)
35 years and







episiotomy 22,839 7.5 309.2 (4525.8)
Cesarean
















5540 8.7 546.6 (7203.0)
Type of birth





preterm birth 1325 8.2 201.6 (999.5)
Pregnancy
pathology 13,697 8.3 399.9 (5550.3)
Total 67,917 7.8 291.5 (3625.7)
DDD—defined daily dose, p—level of significance.
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Table 4. Number of prescriptions and DDD for the second trimester according to place of living,
























16,679 8.7 411.0 (5576.8)
Age
<18 years 393 12.7
p = 0.015
352.5 (1354.1)
p = 0.01418–34 years 57,326 9.1 460.3 (6740.4)
35 years and







episiotomy 22,839 8.8 449.9 (6826.9)
Cesarean
















5540 11.2 858.3 (9446.4)
Type of birth





preterm birth 1325 10.1 329.8 (2411.3)
Pregnancy
pathology 13,697 9.5 696.0 (9850.1)
Total 67,917 9.0 472.4 (6759.9)
DDD—defined daily dose, p—level of significance.
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Table 5. Number of prescriptions and DDD for the third trimester according to place of living,
























16,679 10.0 263.6 (2307.7)
Age




18–34 years 57,326 11.2 285.8 (2219.2)
35 years and







episiotomy 22,839 10.9 266.9 (1995.2)
Cesarean
















5,540 12.4 431.3 (3634.4)
Type of birth





preterm birth 1325 12.8 239.6 (967.1)
Pregnancy
pathology 13,697 11.3 345.6 (2838.4)
Total 67,917 11.2 292.9 (2311.1)
DDD—defined daily dose, p—level of significance.
Most often, antibiotics were purchased by women who delivered in tertiary referral
hospitals and with a multiple or preterm birth. In the case of hospital preferentiality,
these differences were statistically significant in each case, and in women with multi-
ple or preterm childbirth, the lack of statistical significance was found only in the third
trimester. Taking into account the entire period of pregnancy, the average number of
purchase episodes/probable number of infections in one woman was 1.3 (SD 0.70), and in
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individual trimesters, it was 1.1 (SD from 0.24 in the first trimester to 0.38 in the second
and third trimesters).
Most often (94.78% of cases) monotherapy was used, including beta-lactams and
beta-lactams with an inhibitor (67.3%), followed by second-generation cephalosporins
(13.5%), macrolides (14.73%), and others. Prescription of two different preparations was
found in 5.06% of cases, three (0.19%), and four or more (0.03%).
4. Discussion
In the studied group of women giving birth in Małopolska Voivodeship, almost a
quarter, i.e., 23.6% of women filled the prescription for an antibiotic. Most of the pre-
scriptions in general concerned one group of antibiotics, and most often, they were safe
beta-lactam antibiotics. However, the data on prescriptions are very often disturbing in
the youngest patients and in women not living in cities. Andrade et al. [9] report that
as many as 39.8% of all women in the United States received drugs from the group of
antimicrobial drugs, either oral or intravenous—almost twice as much as in our study.
In this analysis, also in individual trimesters, the percentage of prescriptions was about
half lower, although it increased slightly in the second and then third trimesters, and the
American study showed similar prescription rates in individual trimesters. The number of
antibiotic prescriptions recorded in our study is almost two times lower, probably due to
the fact that we only analyzed prescriptions issued by gynecologists and, therefore, related
to genital tract and urinary tract infections, and the American study included all orders,
therefore also infections other than those mentioned.
Indications for antibiotic therapy in outpatient pregnancy services include primarily
the treatment of ascending infections (bacterial vaginosis, urinary tract infections, sexually
transmitted infections) and other infections not related to pregnancy. Schnarr and Smaill
report that urinary tract infections are among the most common bacterial infections in
pregnant women, as 7.4% of the women in their study were diagnosed as having a urinary
tract infection and asymptomatic bacteriuria ranged from 2 to 10% [16]. A meta-analysis
by Azami et al. for the population of Iranian pregnant women showed the prevalence of
asymptomatic bacteriuria to be 8.7% (95% CI: 7.2–10.4), and urinary tract infections–9.8%
(95% CI 7.6–12.5) [21].
Bacterial vaginosis, resulting from the imbalance of the bacterial microbiota in preg-
nant women, as a result of a reduction in the number of Lactobacillus bacteria with a
simultaneous increase in the number of anaerobic bacteria and mycoplasmas, can lead
to serious complications, including premature births, which Leitich et al. confirmed by
a meta-analysis, odds ratio 2.19, 95% confidence level 1.5–3.1 [22,23]. The prevalence of
bacterial vaginosis in pregnancy varies depending on the studied population. In a large
cohort study of 14,193 women in the Nord-Pas de Calais region in France, the incidence
was estimated pursuant to a study based on the Nugent scale at 7.1% (95% CI 6.6–7.5%) [23].
In the Polish population, the prevalence in pregnant women with a normal pregnancy
reaches 1.6% and in women with a risk of preterm labor: 14.2% [13,14]. Thus, urinary tract
infections and genital tract infections, including bacterial vaginosis, represent an important
problem from a public health perspective [13,14,24,25].
In the present data, the antibiotic prescriptions in approximately 23% of pregnant
women may indicate that infections of the genital tract and urinary system in the study
population were in the middle of the ranges reported by the researchers cited above.
However, the association of these data with demographic factors indicate groups of patients
requiring special attention and perinatal care. As in the previous study in the same group,
but with regard to 30 days from the date of delivery, it can be concluded that the need
to use antibiotics is more common in the youngest women, under 18 years of age. The
problem of numerous complications of pregnancy in teenagers, such as pregnancy-induced
hypertension, anemia, and premature birth, has been confirmed by numerous previous
studies [26]. In a study by Oakeshott et al. regarding the relationship between bacterial
vaginosis or chlamydial infection and miscarriages before 16 weeks of gestation, the highest
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prevalence of chlamydial infections in pregnant teenagers was 14.3%, compared to the
average of 2.4% for the entire treatment group and 8.5% in women under 25 years of
age [27]. Therefore, this group of patients requires special perinatal care, similarly to rural
residents, who had the highest percentage of antibiotic orders, taking into account the place
of residence. Thus, there are serious gaps in the prevention and control of infections in the
youngest pregnant women. Urinary tract infections, which are not only the most common
but also the most preventable, can also be a problem. However, this type of intervention
requires knowledge of reproductive health and health promotion in general. This calls for
an urgent need for periodic educational interviews. The effectiveness of integrated, active,
and targeted programs in the prevention of urinary tract infections among pregnant women
was confirmed in a randomized clinical trial by Yazdi et al. [25], and Noroozi et al. [28]. If
an intrauterine infection is suspected or confirmed, antibiotics are also used [29].
According to the classification developed by the American Food And Drug Admin-
istration (FDA), the selection of an antimicrobial drug used during pregnancy should
take into account the proposed classification for drugs according to categories: A, B, C,
D, and X [30]. Category A includes drugs that have not been shown to be harmful in
clinical trials carried out in pregnant women—but none of the antibiotics falls into this
category. Category B comprises drugs that have not shown any risk to the fetus in an-
imal studies, but this has not been confirmed in pregnant women. During pregnancy,
drugs from group B are recommended, including antibiotics from the penicillin group,
cephalosporins, some macrolides (azithromycin, erythromycin), as well as daptomycin
(glycolipopeptides), metronidazole, clindamycin, antifungal antibiotics, and terbotericifin.
This analysis showed that the vast majority of prescriptions concerned drugs belonging
to group B, mainly beta-lactam antibiotics, cephalosporins, and macrolides—about 97%
of all prescriptions. However, approximately 1.3% of the prescriptions were for group C
fluoroquinolones, i.e., drugs that have shown teratogenic and embryotoxic effects in animal
studies and that may only be used when their benefit outweighs the risk of adverse effects
in the fetus. Moreover, about 1% of the prescriptions were orders for preparations from the
tetracycline group, classified as category D, i.e., drugs for which there is a documented risk
to humans. In December 2014, the FDA approved and published a new format and content
for the labeling of medicinal products that abolished the original pregnancy risk category
system for all prescription drugs, approved since June 2001 [31].
Presenting results have some limitations. Firstly, the database did not include, and
the analysis did not encompass, miscarriages. We took into account data on filling the
antibiotic prescriptions ordered by gynecologists in the course of the nine months preceding
childbirth. Consequently, our results are burdened by a few percent bias. We did not have
information about specific indications, but only about prescriptions. However, the value of
our analysis is its pioneering nature, and results indicate areas of perinatal care that require
more thorough research and intervention.
5. Conclusions
Almost a quarter of Polish pregnant women filled a prescription for an antibiotic.
The antibiotic prescriptions in approximately 23% of pregnant women may indicate that
infections of the genital tract and urinary system in the study population were in the middle
of the ranges reported by the most of other studies on this subject. However, an insufficient
number of studies on antibiotic therapy in pregnant women make it impossible to assess
the situation. Additionally, in Poland, the prevalence of gestational infections is unknown,
and their diagnostics is important—especially in relation to microbiological diagnostics
and targeted treatment. Most often—94.78% of cases—monotherapy was used, including
beta-lactams and beta-lactams with an inhibitor (67.3%). This observation was consistent
with the recommendations for antibiotic therapy in pregnancy. However, the present
results indicate the need to implement broad health promotion programs, accessible to all
women, as well as those living outside large cities, particularly promoting the prevention
of urinary tract infections and reproductive health in general.
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7. Różańska, A.; Pac, A.; Romanik, M.; Bulanda, M.; Wójkowska-Mach, J. Outpatient post-partum antibiotic prescription: Method
of identification of infection control areas demanding improvements and verification of sensitivity of infection registration. J.
Antimicrob. Chem. 2018, 73, 240–245. [CrossRef]
8. ECDC: Healthcare-Associated Infections: Surgical Site Infections—Annual Epidemiological Report for 2017. Available online:
https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-surgical-site-infections-annual-1 (accessed
on 19 December 2020).
9. Andrade, S.E.; Gurwitz, J.H.; Davis, R.L.; Chan, K.A.; Finkelstein, J.A.; Fortman, K.; McPhillips, H.; Raebel, M.A.; Roblin, D.;
Smith, D.H.; et al. Prescription drug use in pregnancy. Am. J. Obs. Gynecol. 2004, 191, 398–407. [CrossRef]
10. Ventura, S.J.; Abma, J.C.; Mosher, W.D.; Henshaw, S. Estimated pregnancy rates for the United States. 1990–2000 an update. Nat.
Vital Stat. Rep. 2004, 52, 1–9.
11. Available online: https://stat.gov.pl/obszary-tematyczne/ludnosc/ludnosc/urodzenia-i-dzietnosc,34,1.html (accessed on 19
December 2020).
12. McDonald, H.M.; Brocklehurst, P.; Gordon, A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst.
Rev. 2007, CD000262. [CrossRef]
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